This IP Month, Celebrate American Medical Innovation

October is Intellectual Property (IP) Month, an opportunity to celebrate human achievement and reflect on the foundation of American progress. From lifesaving therapies developed in the medical marketplace to the creative media and breakthrough technologies shaping modern life, our nation’s standard of living is powered by the legal certainty that people’s ideas, investments, and freedom to innovate will be protected.

American leadership in technology and the life sciences is no accident. It is rooted in a specific vision established at the founding of the republic. The Constitution provides explicit protection for intellectual property. Article I, Section 8, Clause 8 empowers Congress: “To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries.”

Centuries later, that framework remains indispensable to fueling the American economic engine. Nowhere is this more evident than in the healthcare sector.

Bringing a breakthrough drug from the lab to market requires, on average, $2.6 billion and 10 to 15 years. Nine out of ten drug candidates (90 percent) fail after entering human clinical trials. If the early preclinical laboratory stages before human testing even begins are factored in, the failure rate is even higher. The drug development process involves years of high-risk research, regulatory hurdles, and frequent failures before achieving a single success.

Strong patents enable innovators to recover the enormous costs of developing new medicines and vaccines. Without dependable IP rights, the market incentives that sustain long-term research and development erode. When governments interfere with intellectual property through compulsory licensing or weakened patent enforcement, promising research is halted and companies cease their investments.

There is a clear relationship between policies that undermine IP and a decline in new medical discoveries. A study analyzing 1,769 unique drug candidates found that when a drug’s underlying patents were revoked or invalidated during clinical trials, companies frequently halted or reduced further development. When government distorts the medical marketplace by compromising IP rights, the cost extends beyond lost revenue; patients pay the ultimate price through missed breakthroughs and cures never developed, resulting in lives lost and destroyed because of illnesses that could be treated.

Threats to IP do not stop at domestic policy disputes; they also cross borders. American companies face persistent pressure from foreign competitors seeking access to proprietary technologies without bearing the enormous costs and risks of developing them. IP-intensive sectors account for a massive 81.5 percent of all U.S. commodity exports, led directly by the aerospace, petroleum, and pharmaceutical industries.

Weakening IP rights through international waivers or tolerating lax patent enforcement abroad undermines private enterprise and rewards those who benefit from innovation without paying for it. Demanding that foreign adversaries such as China stop stealing American IP is essential not only to protect economic growth and individual property rights around the world, but also to preserve America’s national security and competitive advantage in healthcare.

This IP Month, policymakers and citizens alike should recognize that intellectual property is far more than abstract legal theory or opaque corporate strategy. It safeguards the freedom of entrepreneurs to build businesses, creators to pursue their craft, and researchers to tackle humanity’s most complex challenges.

Protecting IP rights helps ensure that the next generation of American innovators can turn bold ideas into reality without runaway subsidies or unnecessary government interference.